Our mission is to develop herpesvirus-based animal vaccines to protect against infectious diseases.
The Vaccine Group (TVG) is using recombinant viral vector technology to develop new vaccines for use in animals, including:
We are creating vaccine delivery platforms for viral and bacterial pathogens to address a growing number of diseases in animals:
• Streptococcus suis
• Porcine reproductive and respiratory syndrome (PRRS)
• Porcine circovirus-2
• Porcine cysticercosis
• Bovine tuberculosis
• Bovine bacterial mastitis
• Bovine respiratory syncytial virus
• African swine fever
• Lumpy skin disease
Latest News
The PRRS Immunology Group at The Pirbright Institute has been awarded an Impact Acceleration Award of £9,000 to progress a novel vaccine for porcine
The Vaccine Group is expanding its repertoire of vaccine candidates as it seeks to maximise the potential of its platform herpesvirus gene delivery system.
Most emerging infectious diseases affecting humans in the last century have originated in animal reservoirs and are defined as zoonotic. Lassa fever is a
Partners
